text: In 2019, the discovery of potent, and selective antagonists of the Luteinizing Hormone Receptor (BAY-298 and BAY-899) were reported which were able to reduce sex hormone levels in vivo. The latter fulfils the quality criteria for a Donated Chemical Probe as defined by the Structural Genomics Consortium.
  A series of thienopyr(im)idine-based compounds leading to optimized Org 43553 were described as the first Luteinizing Hormone Receptor agonists.